News

DMX-200 ACTION3 Trial Maintains Statistical Power Above 90% Following Blinded Data Review

2 min

Concept Medical Presents 3-Year SIRONA Trial Data at Charing Cross Symposium 2026

2 min

Intellia Therapeutics Submits FDA Application for Lonvo-Z, First CRISPR Gene Therapy for Hereditary Angioedema

FDA · Hereditary Angioedema · 3 min

Cordis Launches SELUTION SLR Drug-Eluting Balloon in Japan for Peripheral Artery Disease Treatment

2 min

Tovecimig Shows 56% Reduction in Cancer Progression Risk in Biliary Tract Cancer Trial

2 min

Intellia Therapeutics Achieves First-Ever Positive Phase 3 Results for In Vivo Gene Editing with Lonvoguran Ziclumeran in Hereditary Angioedema

Hereditary Angioedema (HAE) · 3 min

Sagimet Biosciences Plans Phase 3 Denifanstat Trial for Acne Treatment in 2026

2 min

Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment

2 min

Aclaris Therapeutics ATI-052 Phase 1a Trial Results and ATI-2138 Lead Indication Update Set for April 28, 2026

2 min

OSE Immunotherapeutics' Pegrizeprument (VEL-101) Receives FDA Orphan Drug Designation for Heart Transplant Rejection Prevention

FDA · 2 min

Jazz Pharmaceuticals' Ziihera Gets FDA Priority Review for First-Line HER2+ Cancer Treatment

FDA · 2 min

NCCN Adds Nuvation Bio's Taletrectinib (IBTROZI) to Cancer Treatment Guidelines for ROS1-Positive NSCLC with Brain Metastases

2 min